Protalix BioTherapeutics, Inc. (PLX) P/E Ratio History
Historical price-to-earnings valuation from 2015 to 2025
Loading P/E history...
PLX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Protalix BioTherapeutics, Inc. (PLX) trades at a price-to-earnings ratio of -23.5x, with a stock price of $1.98 and trailing twelve-month earnings per share of $-0.08.
The current P/E is 174% below its 5-year average of 32.0x. Over the past five years, PLX's P/E has ranged from a low of 1.2x to a high of 116.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, PLX trades at a 205% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, PLX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PLX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PLX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | - | +68% | |
| $9B | 43.4 | - | +128% | |
| $5B | 8.3Lowest | - | +264%Best | |
| $10B | 30.1 | - | -19% | |
| $8B | 25.5 | 1.11Best | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PLX Historical P/E Data (2015–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $2.22 | $0.07 | 31.5x | -2% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $1.48 | $0.07 | 20.0x | -38% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $2.56 | $0.04 | 60.8x | +90% |
| FY2024 Q4 | $1.88 | $0.03 | 64.2x | +100% | |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $1.26 | $0.05 | 27.9x | -13% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $1.78 | $0.06 | 32.3x | +1% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $1.66 | $0.07 | 25.5x | -20% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $2.00 | $0.02 | 116.3x | +263% |
| FY2016 Q3 | Fri Sep 30 2016 00:00:00 GM | $5.70 | $4.61 | 1.2x | -96% |
| FY2016 Q2 | $6.40 | $4.91 | 1.3x | -96% | |
| FY2016 Q1 | $8.40 | $5.51 | 1.5x | -95% | |
| FY2015 Q4 | $10.20 | $5.81 | 1.8x | -95% |
Average P/E for displayed period: 32.0x
See PLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PLX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPLX — Frequently Asked Questions
Quick answers to the most common questions about buying PLX stock.
Is PLX stock overvalued or undervalued?
PLX trades at -23.5x P/E, below its 5-year average of 32.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does PLX's valuation compare to peers?
Protalix BioTherapeutics, Inc. P/E of -23.5x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is PLX's PEG ratio?
PLX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2015-2025.